Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Account Payables (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Change in Account Payables for 16 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 58.13% year-over-year to $2.1 million, compared with a TTM value of -$5.4 million through Dec 2025, down 399.83%, and an annual FY2025 reading of -$5.4 million, down 399.83% over the prior year.
  • Change in Account Payables was $2.1 million for Q4 2025 at Catalyst Pharmaceuticals, down from $3.6 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $10.2 million in Q4 2023 and bottomed at -$5.7 million in Q2 2025.
  • Average Change in Account Payables over 5 years is $347300.0, with a median of $195500.0 recorded in 2022.
  • Peak annual rise in Change in Account Payables hit 8937.5% in 2022, while the deepest fall reached 873.7% in 2022.
  • Year by year, Change in Account Payables stood at $16000.0 in 2021, then soared by 8937.5% to $1.4 million in 2022, then soared by 605.19% to $10.2 million in 2023, then tumbled by 50.67% to $5.0 million in 2024, then crashed by 58.13% to $2.1 million in 2025.
  • Business Quant data shows Change in Account Payables for CPRX at $2.1 million in Q4 2025, $3.6 million in Q3 2025, and -$5.7 million in Q2 2025.